Simultaneous determination of M-NISOLDIPINE (cas 113578-26-0) and its three metabolites in rat plasma by liquid chromatography–mass spectrometry
-
Add time:08/24/2019 Source:sciencedirect.com
A simple, sensitive and selective liquid chromatography–tandem mass spectrometry (LC–MS/MS) method for the simultaneous determination of M-NISOLDIPINE (cas 113578-26-0) and its three metabolites in rat plasma has been developed using nitrendipine as an internal standard (IS). Following liquid–liquid extraction, the analytes were separated using an isocratic mobile phase on a reverse phase C18 column and analyzed by MS in the multiple reaction monitoring (MRM) mode. To avoid contamination by residual sample in the injection syringe, a special injection protocol was developed. We found that m-nisoldipine, metabolite M1 and IS could be ionized under positive or negative electrospray ionization conditions, whereas metabolite M and M2 could only be ionized in the positive mode. The mass spectrometry fragmentation pathways for these analytes are analyzed and discussed herein. The total analysis time required less than 5 min per sample. We employed this method successfully to study the metabolism of m-nisoldipine when it was orally administered to rats at a dose of 9 mg/kg. Three metabolites of m-nisoldipine and an unknown compound of molecular weight 386 were found for the first time in rat plasma. The concentration of the potentially active metabolite was approximately equal to its parent compound concentration.
We also recommend Trading Suppliers and Manufacturers of M-NISOLDIPINE (cas 113578-26-0). Pls Click Website Link as below: cas 113578-26-0 suppliers
Prev:Thermodynamic stability analysis of M-NISOLDIPINE (cas 113578-26-0) polymorphs
Next:Molecular and Cellular PharmacologyThe inhibitory effects of M-NISOLDIPINE (cas 113578-26-0) on the 5-hydroxytryptamine-induced proliferation of pulmonary artery smooth muscle cells via Ca2+ antagonism and antioxidant mechanisms) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Original ContributionsAntihypertensive monotherapy with nisoldipine CC is superior to enalapril in black patients with severe hypertension08/29/2019
- Cyclic voltammetric behaviour of the O2/O2− redox couple at a HMDE and its interaction with nisoldipine08/28/2019
- Enantioselective assay of nisoldipine in human plasma by chiral high-performance liquid chromatography combined with gas chromatographic−mass spectrometry: applications to pharmacokinetics08/27/2019
- Validated LC–MS–MS method for determination of M-NISOLDIPINE (cas 113578-26-0) polymorphs in rat plasma and its application to pharmacokinetic studies08/26/2019
- Molecular and Cellular PharmacologyThe inhibitory effects of M-NISOLDIPINE (cas 113578-26-0) on the 5-hydroxytryptamine-induced proliferation of pulmonary artery smooth muscle cells via Ca2+ antagonism and antioxidant mechanisms08/25/2019
- Thermodynamic stability analysis of M-NISOLDIPINE (cas 113578-26-0) polymorphs08/23/2019
- Short communicationStudy of in vitro metabolism of M-NISOLDIPINE (cas 113578-26-0) in human liver microsomes and recombinant cytochrome P450 enzymes by liquid chromatography–mass spectrometry08/22/2019
- Short communicationStudies on separation and pharmacokinetics of M-NISOLDIPINE (cas 113578-26-0) enantiomers in beagle dog plasma by LC/MS/MS08/21/2019
- Original articleOn the dimorphism and the pressure–temperature state diagram of racemic M-NISOLDIPINE (cas 113578-26-0), a dihydropyridine calcium ion antagonistSur le dimorphisme et le diagramme d’état pression-température de la M-NISOLDIPINE (cas 113578-26-0) racémique, une dihydroyridine antagoniste08/20/2019